Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

SELEGILINE 5 MG

SELEGILINE HYDROCHLORIDE : 5 MG · DIN 02230641 · AA PHARMA INC

Health Canada status: MARKETED

What is SELEGILINE?

SELEGILINE 5 MG contains SELEGILINE HYDROCHLORIDE : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02230641, held by AA PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 23-Aug-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is SELEGILINE used for?

SELEGILINE (selegiline hydrochloride) may be of value: – as an adjunct to levodopa (with or without a decarboxylase inhibitor) in the management of the signs and symptoms of Parkinson’s Disease. – in newly diagnosed patients before symptoms begin to affect the patient’s social or professional life, at which time more efficacious treatment becomes necessary.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02230641
Brand nameSELEGILINE
Generic / active ingredientSELEGILINE HYDROCHLORIDE : 5 MG
ManufacturerAA PHARMA INC
Strength5 MG
Dosage formTABLET
Route of administrationORAL
SchedulePrescription
ATC codeN04BD01 SELEGILINE
AHFS class28:36.32
BiosimilarNo
Health Canada statusMARKETED
Status date23-Aug-2021
Original market date1997-02-13 00:00:00

How is it administered?

10 mg per day administered as divided doses of 5 mg each taken at breakfast and lunch. Do not exceed 10 mg/day. Levodopa dose may need reduction by 10-30% when starting adjunctive therapy.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Store at room temperature 15°C to 30°C. Protect from light.

How is it supplied?

Bottles of 100

Contraindications

Hypersensitivity; extrapyramidal disorders (e.g., excessive tremor, tardive dyskinesia); severe psychosis; profound dementia; active peptic ulcer; combination with meperidine or other opioids.

Warnings and precautions

Do not exceed 10 mg/day to maintain MAO-B selectivity. Risk of hypertensive crisis (cheese reaction) at higher doses. Serious CNS events when combined with TCAs or SSRIs.

What can be used instead?

Other Canadian products sharing ATC code N04BD01 SELEGILINE. 1 of 11 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
DOM-SELEGILINE5 MGTABLETDOMINION PHARMACALCANCELLED POST MARKETDIN 02238340
ELDEPRYL - 5MG TAB5 MGTABLETDRAXIS HEALTH INC.CANCELLED POST MARKETDIN 02123312
ELDEPRYL TAB 5MG5 MGTABLETDEPRENYL RESEARCH LTD.CANCELLED POST MARKETDIN 00791091
MED SELEGILINE5 MGTABLETMEDICAN PHARMA INCORPORATEDCANCELLED POST MARKETDIN 02237289
MYLAN-SELEGILINE5 MGTABLETMYLAN PHARMACEUTICALS ULCCANCELLED POST MARKETDIN 02231036
NU-SELEGILINE5 MGTABLETNU-PHARM INCCANCELLED POST MARKETDIN 02230717
PMS-SELEGILINE5 MGTABLETPHARMASCIENCE INCCANCELLED POST MARKETDIN 02238102
SELEGILINE5 MGTABLETPHARMEL INCCANCELLED POST MARKETDIN 02238319
SELEGILINE-55 MGTABLETPRO DOC LIMITEECANCELLED POST MARKETDIN 02231479
TEVA-SELEGILINE5 MGTABLETTEVA CANADA LIMITEDCANCELLED POST MARKETDIN 02068087

Who else supplies SELEGILINE worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. SELEGILINE appears in 11 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for SELEGILINE

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for SELEGILINE

Health Canada Drug Product Database (DPD), DIN 02230641. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.